Abstract

The present invention relates to methods of using CCR1 antagonists as immunomodulatory agents. In particular, the present invention relates to methods of using heteroaryl-hexanoic acid amide derivatives of the formula (I)

$$R^{1} \xrightarrow{N} H \xrightarrow{QH} R^{3}$$
 (I)

wherein R¹, R², R³, and Y are as described in the specification.

5